JP2024507938A5 - - Google Patents

Info

Publication number
JP2024507938A5
JP2024507938A5 JP2023551767A JP2023551767A JP2024507938A5 JP 2024507938 A5 JP2024507938 A5 JP 2024507938A5 JP 2023551767 A JP2023551767 A JP 2023551767A JP 2023551767 A JP2023551767 A JP 2023551767A JP 2024507938 A5 JP2024507938 A5 JP 2024507938A5
Authority
JP
Japan
Prior art keywords
agent according
formula
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507938A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017678 external-priority patent/WO2022182857A1/en
Publication of JP2024507938A publication Critical patent/JP2024507938A/ja
Publication of JP2024507938A5 publication Critical patent/JP2024507938A5/ja
Pending legal-status Critical Current

Links

JP2023551767A 2021-02-25 2022-02-24 骨髄線維症の治療としてのbet阻害剤の使用 Pending JP2024507938A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21382163 2021-02-25
EP21382163.0 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US63/232,866 2021-08-13
US202263297098P 2022-01-06 2022-01-06
US63/297,098 2022-01-06
PCT/US2022/017678 WO2022182857A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Publications (2)

Publication Number Publication Date
JP2024507938A JP2024507938A (ja) 2024-02-21
JP2024507938A5 true JP2024507938A5 (cg-RX-API-DMAC7.html) 2025-03-04

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551767A Pending JP2024507938A (ja) 2021-02-25 2022-02-24 骨髄線維症の治療としてのbet阻害剤の使用

Country Status (12)

Country Link
US (2) US12357621B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297750A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507938A (cg-RX-API-DMAC7.html)
KR (1) KR20230148208A (cg-RX-API-DMAC7.html)
AU (1) AU2022227673B2 (cg-RX-API-DMAC7.html)
CA (1) CA3206708A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002497A1 (cg-RX-API-DMAC7.html)
IL (1) IL304697A (cg-RX-API-DMAC7.html)
MX (1) MX2023009858A (cg-RX-API-DMAC7.html)
TW (1) TW202302095A (cg-RX-API-DMAC7.html)
WO (1) WO2022182857A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307538B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP4351560A4 (en) 2021-06-08 2025-06-04 The Regents of the University of California ANTI-CANCER COMPOUNDS
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA201990240A1 (ru) * 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
DK3908281T3 (da) * 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Similar Documents

Publication Publication Date Title
JP2024133474A5 (cg-RX-API-DMAC7.html)
JP2024133475A5 (cg-RX-API-DMAC7.html)
JP2022009090A5 (cg-RX-API-DMAC7.html)
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
JP2022545005A5 (cg-RX-API-DMAC7.html)
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
JP2011503063A5 (cg-RX-API-DMAC7.html)
JP2012520313A5 (cg-RX-API-DMAC7.html)
JP2018526376A5 (cg-RX-API-DMAC7.html)
JP2021509680A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
EA037152B1 (ru) Способ лечения рака
JP2014512356A5 (cg-RX-API-DMAC7.html)
JP2009514870A5 (cg-RX-API-DMAC7.html)
JP2022540421A5 (cg-RX-API-DMAC7.html)
JP2020523354A5 (cg-RX-API-DMAC7.html)
JP2014524469A5 (cg-RX-API-DMAC7.html)
JP2016502981A5 (cg-RX-API-DMAC7.html)
JP2014512355A5 (cg-RX-API-DMAC7.html)
JP2023548190A5 (cg-RX-API-DMAC7.html)
CN103533940A (zh) 治疗晚期实体瘤的方法
AU2017205749A1 (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
JP2015517523A5 (cg-RX-API-DMAC7.html)
JP2018516936A5 (cg-RX-API-DMAC7.html)
JP2021534160A5 (cg-RX-API-DMAC7.html)